The Chinese mainland is poised to become a major player in the biopharmaceutical industry, driving innovation and creating well-paid jobs, according to Pascal Soriot, CEO of AstraZeneca. During an interview at the Boao Forum for Asia Annual Conference 2024, Soriot highlighted the Chinese mainland's focus on developing new quality productive forces. This strategic emphasis on biopharma not only boosts the economy but also enhances global health advancements.
Reference(s):
cgtn.com
